Is AOD-9604 Legal in Louisiana? How to Access It Legally

What Is AOD-9604 and Why Does Its Legal Status Matter?

AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH), specifically amino acids 176 to 191. Researchers originally investigated it as a potential anti-obesity agent because it appeared to stimulate lipolysis without producing the insulin-desensitizing effects associated with full-length hGH. Its legal status matters because federal classification drives what compounding pharmacies, physicians, and patients can legally do with it.

The Peptide's Mechanism

AOD-9604 binds to beta-3 adrenergic receptors in adipose tissue, theoretically accelerating fat breakdown and slowing lipogenesis. Early animal data published in studies indexed on PubMed showed promising lipolytic effects, but human translation proved inconsistent. The peptide does not bind the IGF-1 receptor at standard doses, which distinguishes it mechanistically from full-length growth hormone and from IGF-1 secretagogues such as ipamorelin or CJC-1295. [1]

Why Regulatory Classification Is Not Straightforward

AOD-9604 has never received an approved New Drug Application (NDA) from the FDA. Metabolic Pharmaceuticals Ltd. Conducted Phase II human trials in the early 2000s under the investigational name Tyr-hGH 177-191, but the compound did not meet primary endpoints for statistically significant weight reduction in the key human studies. The FDA's Drugs@FDA database confirms no approved application exists for AOD-9604. [2] Without an approved NDA or an abbreviated NDA, AOD-9604 cannot be marketed as a finished pharmaceutical product in the United States.

This absence of approval is the root of every downstream legal question. Because no finished drug exists, the only legal pathway for patient access runs through the compounding framework established by Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Drug Quality and Security Act (DQSA) of 2013. The full text of the DQSA and its compounding provisions is available on the FDA's website. [3]

Federal Regulatory Framework: 503A vs. 503B

The two compounding pathways differ in scope, oversight intensity, and permitted bulk drug substances. Getting this distinction right is the single most consequential factor for Louisiana patients and prescribers.

Section 503A: Traditional Compounding Pharmacies

Section 503A of the FD&C Act governs traditional, patient-specific compounding performed by state-licensed pharmacies. A 503A pharmacy may compound a drug using a bulk drug substance only if that substance:

1. Appears on the FDA's 503A bulk drug substances list (the so-called "positive list"), OR
2. Has a United States Pharmacopeia (USP) or National Formulary (NF) monograph, OR
3. Was commercially available before 1962 and is not a component of an FDA-approved drug that has been withdrawn from the market for safety or efficacy reasons.

FDA's current guidance on 503A bulk drug substance nominations and categories is published at fda.gov. [4] AOD-9604 does not have a USP monograph. It was not commercially available before 1962. Whether it meets the third criterion depends on whether the FDA formally places it on a negative list or a Category 1 positive list.

As of mid-2024, AOD-9604 has not been placed on the FDA's Category 1 positive list for 503A compounding, but it also has not been explicitly prohibited on a Category 2 negative list specific to 503A. This regulatory silence is the gray area that compounding pharmacies and prescribers currently operate within. Pharmacies that compound AOD-9604 under 503A cite the absence of an explicit prohibition, but this position carries compliance risk if the FDA later issues a formal negative determination.

Section 503B: Outsourcing Facilities

Section 503B outsourcing facilities operate under current Good Manufacturing Practice (cGMP) standards and may produce larger batches without individual patient prescriptions. However, 503B facilities are restricted to bulk drug substances that appear on the FDA's explicit Category 1 list for 503B. The FDA's 503B bulk drug substance list is maintained and updated at fda.gov. [5]

AOD-9604 does not appear on the 503B Category 1 approved list. A 503B facility that compounds AOD-9604 without explicit FDA authorization would be operating outside the statutory framework. Louisiana patients ordering from a 503B source that claims AOD-9604 availability should request documentation of the facility's registration and the specific bulk substance authorization.

Louisiana State Law and the Board of Pharmacy

Louisiana does not have a separate state-level statute that independently legalizes or prohibits AOD-9604. Louisiana pharmacy law defers to the federal compounding framework for prescription compounding, but the Louisiana Board of Pharmacy (LBP) adds its own licensing and practice standards on top of federal baseline requirements.

Louisiana Board of Pharmacy Oversight

The LBP licenses all pharmacies operating within the state, including compounding pharmacies. Any 503A pharmacy dispensing AOD-9604 to Louisiana patients must hold a valid LBP license. Out-of-state compounding pharmacies shipping into Louisiana must hold a non-resident pharmacy permit issued by the LBP. Patients can verify a pharmacy's Louisiana licensure through the LBP's online verification portal. Louisiana's pharmacy practice act and rules are codified under Louisiana Revised Statutes Title 37, Chapter 14, which the LBP enforces in alignment with federal compounding regulations. [6]

The Medical Practice Act and Prescriber Authority

Louisiana physicians licensed under the Louisiana Medical Practice Act may prescribe compounded preparations, including peptides, for patients when the physician determines a compounded product is medically necessary. Nurse practitioners and physician assistants with prescriptive authority under Louisiana law may also prescribe compounded medications within their scope of practice. The Louisiana State Board of Medical Examiners governs physician licensure and prescribing standards. [7]

A prescription for AOD-9604 must follow all standard prescription requirements: patient name, date, prescriber DEA or state license number (if applicable), the specific compounded formulation requested, dosing instructions, and quantity. AOD-9604 is not a controlled substance under the federal Controlled Substances Act, so DEA scheduling does not apply. The DEA's list of controlled substances is searchable at the DEA Diversion Control Division website, and AOD-9604 does not appear. [8]

Clinical Evidence Supporting (and Limiting) Medical Prescribing

Prescribing a compounded drug for a patient requires a legitimate clinical rationale. A brief review of the human trial data helps frame what physicians can and cannot claim when writing a compounded AOD-9604 prescription.

Phase II Trial Data

Metabolic Pharmaceuticals conducted a double-blind, placebo-controlled Phase II trial in overweight adults using oral AOD-9604 at doses ranging from 1 mg to 54 mg daily over 12 weeks. Results published in indexed literature showed no statistically significant difference in weight loss between AOD-9604 and placebo at any dose tested. [9] The lack of efficacy signal in the key human trial was the primary reason the compound did not advance to Phase III or NDA submission.

Injectable formulations have been studied in preclinical models with more encouraging lipolytic data, but no large-scale, peer-reviewed randomized controlled trial of injectable AOD-9604 in humans has been published in a major indexed journal as of mid-2024. A PubMed search for "AOD-9604 human trial" retrieves fewer than 15 indexed results, which underscores the limited evidentiary base. [10]

What the Evidence Does and Does Not Support

Physicians considering AOD-9604 for weight management should note that the existing approved pharmacotherapy options carry far stronger evidence. Semaglutide 2.4 mg (Wegovy) produced 14.9% mean body weight loss at 68 weeks in STEP-1 (N=1,961) vs. 2.4% for placebo (P<0.001). The STEP-1 trial results are published in the New England Journal of Medicine. [11] Tirzepatide 15 mg (Zepbound) produced 20.9% mean weight loss at 72 weeks in the SURMOUNT-1 trial (N=2,539). SURMOUNT-1 data are available in the New England Journal of Medicine. [12]

The American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines recommend FDA-approved pharmacotherapy as the first-line adjunct to lifestyle intervention. AACE guidelines are available at aace.com. [13] AOD-9604 does not appear in these guidelines because it lacks an approved indication.

The Step-by-Step Legal Access Path for Louisiana Patients

The pathway below reflects the most defensible legal route for a Louisiana resident seeking compounded AOD-9604 in 2024.

Step 1: Establish Care With a Licensed Louisiana Prescriber

A patient must first establish a legitimate patient-provider relationship. This may occur in person or via telemedicine. Louisiana's telemedicine rules, updated in 2020, permit prescribing via synchronous audio-video visits after an appropriate evaluation. Louisiana telemedicine regulations align with the Louisiana Revised Statutes and are referenced in context by the Federation of State Medical Boards. [14] A prescriber who issues a compounded peptide prescription without conducting a proper evaluation risks disciplinary action from the Louisiana State Board of Medical Examiners.

Step 2: The Prescriber Documents Medical Necessity

The prescription must be based on documented medical necessity. For AOD-9604, this typically means the prescriber charts the patient's weight history, prior treatment attempts, and the clinical reasoning for selecting a compounded peptide over approved alternatives. A prescription written without charted clinical rationale is a compliance liability for the prescriber.

Step 3: Identify a 503A-Compliant Compounding Pharmacy

The patient or prescriber identifies a 503A compounding pharmacy that:

• Holds an active LBP license (or a Louisiana non-resident pharmacy permit for out-of-state pharmacies).
• Has passed state and federal inspection without consent decrees or warning letters related to sterile compounding.
• Can document that the bulk AOD-9604 substance it uses comes from an FDA-registered bulk drug manufacturer.

The FDA maintains a list of registered human drug manufacturers and bulk drug substance suppliers that pharmacies can and should use to verify supply chain compliance. [15]

Step 4: Prescription Dispensed and Delivered

Once the pharmacy receives a valid prescription, it compounds the preparation per the prescriber's specifications and ships or dispenses it to the patient. Interstate shipping of compounded prescriptions is legal when the receiving state (Louisiana) does not specifically prohibit the out-of-state compounder from shipping, and when the out-of-state pharmacy holds a Louisiana non-resident permit.

Step 5: Ongoing Monitoring

AOD-9604 has no FDA-approved dosing protocol. Physicians typically prescribe subcutaneous injections in the range of 250 to 500 mcg once daily, based on compounding pharmacy dosing guides and limited clinical literature. A review of peptide-based pharmacology published in Endocrine Practice summarizes general considerations for compounded peptide use in clinical settings. [16] The prescribing physician should schedule follow-up visits at 4 to 8 week intervals to assess response, adverse effects, and whether continued use is clinically justified.

What Is Not Legal: Common Mistakes Louisiana Patients Make

Several actions that appear convenient are legally problematic.

Purchasing "Research Use Only" AOD-9604

Websites selling AOD-9604 labeled "for research use only" or "not for human use" are not dispensing a legal pharmaceutical preparation. Purchasing such products for human injection violates the FD&C Act's prohibitions on unapproved new drugs. The FDA has issued multiple warning letters to peptide vendors operating in this space. One such FDA warning letter regarding unapproved peptide products was issued in 2022 and is available at accessdata.fda.gov. [17]

Importing AOD-9604 From Foreign Suppliers

Importing unapproved drugs from foreign pharmacies or chemical suppliers for personal use is not protected by a formal FDA personal importation policy for injectable peptides. The FDA's personal importation policy applies narrowly to approved foreign drugs not available in the US, not to research chemicals. FDA's personal importation policy is described at fda.gov. [18]

Receiving AOD-9604 From a 503B Facility Without Authorization

As noted above, 503B outsourcing facilities cannot legally compound AOD-9604 without it appearing on the 503B Category 1 bulk substance list. A patient who receives AOD-9604 from a facility claiming 503B status should verify whether that facility is actually a 503A state-licensed pharmacy operating under a different designation.

Physician and Pharmacist Liability Considerations

Both prescribers and dispensing pharmacists carry liability when compounding falls outside the legal framework.

Prescriber Risk

A Louisiana physician who prescribes AOD-9604 for a use that cannot be supported by any reasonable clinical evidence, or who fails to document the patient encounter adequately, may face scrutiny from the Louisiana State Board of Medical Examiners. The board evaluates prescribing against the standard of care, which for weight management is defined primarily by AACE, the Endocrine Society, and the American Heart Association. The Endocrine Society's obesity management guidelines, published in the Journal of Clinical Endocrinology and Metabolism, set the benchmarks used in disciplinary reviews. [19]

Pharmacist Risk

A compounding pharmacist who uses bulk AOD-9604 from an unregistered supplier, or who compounds without a valid patient-specific prescription, violates 503A requirements and may face LBP sanctions, FDA inspection findings, and potential federal enforcement. The USP chapter on pharmaceutical compounding (USP Chapter 795 for non-sterile, USP Chapter 797 for sterile preparations) sets the quality standards pharmacists must meet. USP Chapter 797 standards are referenced by the FDA in its sterile compounding guidance. [20]

Comparing AOD-9604 Access to Approved Alternatives in Louisiana

Louisiana patients who want legal, evidence-backed weight-loss pharmacotherapy have several options that do not carry the regulatory uncertainty of AOD-9604.

Semaglutide (Ozempic/Wegovy), liraglutide (Saxenda), tirzepatide (Zepbound), and naltrexone-bupropion (Contrave) are all FDA-approved, carry substantial randomized controlled trial data, and are available through standard Louisiana retail pharmacies with a prescription. The FDA's approved drug products database (Orange Book) lists all current approvals. [21]

Compounded semaglutide became widely available during the 2023 to 2024 shortage period, but the FDA has indicated it will re-evaluate this allowance as shortage status changes. The FDA's GLP-1 shortage page is updated regularly at fda.gov. [22] Patients whose clinical picture supports GLP-1 therapy should discuss FDA-approved options with their provider before considering compounded peptides with a weaker evidence base.